9results about How to "Minimally invasive" patented technology

The invention relates to a remote control pelvic fracture reduction system, which comprises a man-machine interaction automatic control unit, more than two servo driving systems and more than two pelvic rotary push-pull devices, and the man-machine interaction automatic control unit interacts through a man-machine interaction interface. A reset path automatic planning strategy is formulated based on an artificial intelligence algorithm of a pelvis unlocking reset path, and then servo driving of a high-precision servo motor is provided by each servo driving system according to the reset path automatic planning strategy; then, the pelvic rotating push-pull devices connected with the pelvic rotating push-pull devices are driven to execute axial displacement push-pull reduction actions in respective directions on the pelvic fracture blocks of the patient, so that cooperative and consistent multi-degree-of-freedom space linkage of the pelvic fracture blocks of the patient is completed, and angular rotation and axial push-pull reduction on a plurality of two-dimensional planes under remote automatic control are realized; intelligent, precise and minimally invasive reduction of serious displacement pelvic fracture is achieved, the access threshold of pelvic fracture treatment is lowered, and meanwhile perspective radiation injuries to medical staff and patients are reduced.

The present invention provides a microneedle biosensor including a working electrode including a first base of a circular thin film type, a plurality of microneedles which perpendicularly protrudes on the first base, and a first wiring line which extends from one end of a circumference of the first base; a counter electrode which includes a second base of a strip thin film type having a 3 / 4 circular shape which is spaced apart from a circumference of the first base with a setting distance to be concentric with the first base, a plurality of microneedles which perpendicularly protrudes on the second base, and a second wiring line which extends from one end of the second base to be horizontally disposed with the first wiring line; and a reference electrode which includes a third base of a strip thin film type having a 1 / 4 circular shape which is spaced apart from the other end of the second base with a setting distance and is spaced apart from the circumference of the first base with a setting distance to be concentric with the first base, a plurality of microneedles which perpendicularly protrudes on the third base, and a third wiring line which extends from one end of the third base, and a manufacturing method thereof.

This application discloses a hydrogel composition, its preparation method, and its applications, relating to the fields of regenerative medicine and biomedical materials technology. The hydrogel composition comprises o-nitrobenzyl alcohol-modified tetra-arm polyethylene glycol and methacrylated hyaluronic acid. The hydrogel composition provided in this application addresses the problems in related technologies that rely on tissue flaps or prostheses for repair, such as large trauma, easy foreign body reaction, asymmetrical shape, unnatural feel, and the inability of tissue engineering materials to be rapidly molded intraoperatively, requiring secondary surgery.

The application discloses a plasma metabolic marker composition and a screening method and application thereof, and relates to the technical field of biomedicine. The plasma metabolic marker composition comprises glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-formic acid and phosphatidylethanolamine 36:2p. The metabolic marker composition is significantly different in different cancer types, can distinguish different cancer types of cancer patients, and realizes the detection of pan-cancer. The metabolic marker composition is non-invasive and minimally invasive when used for the detection of pan-cancer, is more suitable for the screening and detection of a large number of ordinary people, has high sensitivity and specificity, is more suitable for the early screening of cancer, and is helpful for the early screening, early diagnosis and early treatment of cancer, and is helpful for improving the survival rate and cure rate of cancer patients.

This invention proposes a mitral valve capture mechanism for transcatheter interventional therapy, comprising: a capture unit, sleeved outside a control rod and located behind a clamping device, comprising: a base with an axially extending through-hole for the control rod to pass through, the front end of which is connected to a plurality of circumferentially distributed shape memory alloy units; a rigid unit, correspondingly arranged and connected to the shape memory alloy units, comprising an anterior rigid plate and a posterior rigid plate, wherein the anterior and posterior rigid plates do not contact each other, nor does the posterior rigid plate contact the base; a limiting ring, located in front of the shape memory alloy units and connected to the anterior rigid plate; a first cable control unit and a second cable control unit. This invention can effectively solve the problem of valve floating due to blood flow during mitral valve edge-to-edge repair, leading to clamping failure.

The invention relates to a biochemical diagnostic test performed on peripheral blood, which allows the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). Specifically, the serum levels of at least 6 markers corresponding to 2 groups of functional lipids, sphingolipids and long-chain polyunsaturated fatty acids (LC-PUFAs) are measured, specifically: Ceramide C16:0, Ceramide C24:0, Deoxy dihydro-ceramide C24:1 and Sphinganin 1-phosphate, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), detecting a variation in concentrations with respect to the values for the control population.

The invention relates to a biochemical diagnostic test performed on peripheral blood, which allows the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). Specifically, the serum levels of at least 6 markers corresponding to 2 groups of functional lipids, sphingolipids and long-chain polyunsaturated fatty acids (LC-PUFAs) are measured, specifically: Ceramide C16:0, Ceramide C24:0, Deoxy dihydro-ceramide C24:1 and Sphinganin 1-phosphate, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), detecting a variation in concentrations with respect to the values for the control population.

The invention provides a hydrogel composite microneedle as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing a mixed solution from a sodium hydroxide solution and a phosphate solution; a uniform and transparent solution is obtained from the low-molecular sodium hyaluronate and the mixed solution; obtaining a first uniform solution from the uniform transparent solution, N, N-dimethylformamide and methacrylic anhydride; adjusting the pH value of the first uniform solution to obtain a second uniform solution; utilizing the second uniform solution to obtain a white flocculent solution; obtaining a white precipitate through the white flocculent solution; dissolving the white precipitate in ultrapure water, and dialyzing to obtain dialyzed liquid; performing vacuum freeze drying on the dialyzed liquid to obtain a MeHA solid; obtaining an M-G solution through the MeHA solid; and obtaining the hydrogel composite microneedle by using the M-G solution. According to the method, the sample extraction efficiency is improved through an extraction and detection two-step method, and stable signals can be kept in the detection process.

The application discloses application of exosome miRNA markers in evaluation of curative effect of immunotherapy combined with chemotherapy on small cell lung cancer patients. The exosome miRNA markers are a combination of miR-338-5p, miR-345-5p, miR-150-5p, miR-7706 and miR-328-3p. It is found for the first time that a combination of plasma exosome miRNA and TNM stage can be used as a marker to effectively predict a population benefiting from an immunotherapy combined with chemotherapy treatment scheme. Due to the unique structure of the exosome and the advantages of liquid biopsy technology, the exosome miR-338-5p, miR-345-5p, miR-150-5p, miR-7706, miR-328-3p and TNM stage combination of the application has high sensitivity and convenience as a population screening for benefiting from an immunotherapy combined with chemotherapy combined treatment scheme.